Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real‐life experience and therapeutic response to other biological drugs

Adalimumab is the only biological drug approved to date for the treatment of moderate and/or severe hidradenitis suppurativa. Adverse events reported during therapy include paradoxical psoriasiform reactions. No guidelines are currently available for the management of this clinical condition. The ai...

Descripción completa

Detalles Bibliográficos
Autores principales: Burzi, Lorenza, Repetto, Federica, Ribero, Simone, Mastorino, Luca, Quaglino, Pietro, Dapavo, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078212/
https://www.ncbi.nlm.nih.gov/pubmed/36175129
http://dx.doi.org/10.1111/dth.15866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078212/
https://www.ncbi.nlm.nih.gov/pubmed/36175129
http://dx.doi.org/10.1111/dth.15866

Ejemplares similares